# Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

> **NCT02268045** · PHASE3 · COMPLETED · sponsor: **mAbxience Research S.L.** · enrollment: 272 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** RTXM83
- **BIOLOGICAL:** Mabthera

## Key facts

- **NCT ID:** NCT02268045
- **Lead sponsor:** mAbxience Research S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2016-05
- **Final completion:** 2017-07
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2019-09-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02268045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02268045, "Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02268045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*